A SPECIFIC, SENSITIVE RADIOIMMUNOASSAY FOR PLATELET-ACTIVATING FACTOR (PAF)

被引：28

作者：

SMAL, MA

BALDO, BA

MCCASKILL, A

机构：

[1] ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA

[2] SILENUS LABS PTY LTD,HAWTHORN,VIC 3122,AUSTRALIA

[3] UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA

来源：

JOURNAL OF IMMUNOLOGICAL METHODS | 1990年 / 128卷 / 02期

关键词：

Anti-platelet-activating factor; Platelet-activating factor; Platelet-activating factor radioimmunoassay; Quantitation of platelet-activating factor;

D O I：

10.1016/0022-1759(90)90209-E

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A specific radioimmunoassay (RIA) has been developed for platelet-activating factor (PAF) and shown to be sensitive over the range 10-1000 pg (0.02-2 pmol). The anti-PAF antibodies showed specificity for the acetyl group at the C2 position of the PAF molecule and exhibited no significant cross-reactivity with lyso-PAF or the naturally occurring lipids including lecithin and lysolecithin. The sensitivity of the RIA was at least as good as the platelet-based assays for PAF but the RIA was simpler to perform, had a higher capacity and did not have the drawback of the inherent variability associated with the bioassays. © 1990.

引用

收藏

页码：183 / 188

页数：6

相关论文

共 50 条

[31] A glucose-containing ether lipid (Glc-PAF) as an antiproliferative analogue of the platelet-activating factor [J].

Mickeleit, M ;

Wieder, T ;

Arnold, M ;

Geilen, CC ;

Mulzer, J ;

Reutter, W .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1998, 37 (03) :351-353

[32] Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2) [J].

Stafforini, Diana M. .

CARDIOVASCULAR DRUGS AND THERAPY, 2009, 23 (01) :73-83

[33] Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2) [J].

Diana M. Stafforini .

Cardiovascular Drugs and Therapy, 2009, 23 :73-83

[34] The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide [J].

Maniscalco, M ;

Sofia, M ;

Faraone, S ;

Carratù, L .

ALLERGY, 2000, 55 (08) :757-761

[35] Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients [J].

Harishkumar, Rajendran ;

Hans, Sakshi ;

Stanton, Janelle E. ;

Grabrucker, Andreas M. ;

Lordan, Ronan ;

Zabetakis, Ioannis .

NUTRIENTS, 2022, 14 (20)

[36] Effects of platelet-activating factor and platelet-activating factor: acetylhydrolase on in vitro post-thaw boar sperm parameters [J].

Bathgate, R. ;

Maxwell, W. M. C. ;

Evans, G. .

THERIOGENOLOGY, 2007, 67 (04) :886-892

[37] Current status of platelet-activating factor antagonists [J].

Curtin, ML .

EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (06) :703-711

[38] Platelet-activating factor and edema surrounding meningiomas [J].

Hirashima, Y ;

Hayashi, N ;

Fukuda, O ;

Ito, H ;

Endo, S ;

Takaku, A .

JOURNAL OF NEUROSURGERY, 1998, 88 (02) :304-307

[39] Platelet-activating factor acetylhydrolases in health and disease [J].

Tjoelker, LW ;

Stafforini, DM .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1488 (1-2) :102-123

[40] Platelet-activating factor and normal or leukaemic haematopoiesis [J].

Denizot, Y ;

Guglielmi, L ;

Donnard, M ;

Trimoreau, F .

LEUKEMIA & LYMPHOMA, 2003, 44 (05) :775-782

← 1 2 3 4 5 →